Last 11.20
Change Today 0.00 / 0.00%
Volume 0.0
EXEN On Other Exchanges
Tel Aviv
As of 10:24 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

exalenz bioscience ltd (EXEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/30/13 - $22.50
52 Week Low
08/27/14 - $10.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

exalenz bioscience ltd (EXEN) Related Businessweek News

No Related Businessweek News Found

exalenz bioscience ltd (EXEN) Details

Exalenz Bioscience Ltd. develops and commercializes breath test-based point-of-care disease management systems for gastrointestinal and liver disorders in Israel and internationally. It offers BreathID Hp, a urea breath test for diagnosing H. pylori infection; and for post-treatment monitoring of H. pylori infection in adults in the areas of primary care, gastric distress, bariatric surgery, and emergency room. The company is based in Modiin, Israel.

exalenz bioscience ltd (EXEN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

exalenz bioscience ltd (EXEN) Key Developments

Exalenz Bioscience Ltd, Special/Extraordinary Shareholders Meeting, Jul 15, 2014

Exalenz Bioscience Ltd, Special/Extraordinary Shareholders Meeting, Jul 15, 2014., at 10:00 Israel Standard Time.

Exalenz Bioscience Expands its Breath Testing Technology into the Potential Billion Dollar Liver Diagnostic Market

Exalenz Bioscience's Board of Directors has approved pursuing the development of liver diagnostics in four medical indications: Clinically Significant Portal Hypertension (CSPH), Nonalcoholic Steatohepatitis (NASH), Hepatocellular Carcinoma (HCC), and Acute Liver Failure (ALF). Exalenz, which develops and markets unique diagnostic and monitoring systems for the diagnosis and management of digestive tract and liver diseases, reports that the company's Board of Directors has approved a strategic and tactical plan, expanding and accelerating the company's activity in the field of liver diagnostics. Exalenz is expected to commence its pivotal Phase III trial in the third quarter of 2014, for the diagnosis of clinically significant portal hypertension (CSPH). Working with the FDA, Exalenz has developed an approach to the diagnosis of CSPH comparing breath testing to HVPG (Hepatic Vein Venus Pressure) that will be submitted with the conclusion of the clinical study. CSPH is considered the accepted indication for liver cirrhosis severity assessment. The market potential for the developed diagnostic test is estimated by Exalenz at $100 million a year.

Exalenz Bioscience Ltd, Special/Extraordinary Shareholders Meeting, Feb 25, 2014

Exalenz Bioscience Ltd, Special/Extraordinary Shareholders Meeting, Feb 25, 2014., at 10:00 Israel Standard Time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEN:IT 11.20 0.00

EXEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EXEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation EXEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXALENZ BIOSCIENCE LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at